EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ionis Pharmaceuticals's enterprise value is $5,949.6 Mil.
Ionis Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $717.3 Mil. Therefore, Ionis Pharmaceuticals's EV-to-Revenue for today is 8.30.
The historical rank and industry rank for Ionis Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
IONS'
s EV-to-Revenue Range Over the Past 10 Years
Min: 4.14 Med: 8.51 Max: 26.79
Current: 8.3
During the past 13 years, the highest EV-to-Revenue of Ionis Pharmaceuticals was 26.79. The lowest was 4.14. And the median was 8.51.
IONS's EV-to-Revenue is ranked worse than 50.55% of 993
companies
in the Biotechnology industry
Industry Median: 8.26
vs IONS: 8.30
Ionis Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for Ionis Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ionis Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Ionis Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's EV-to-Revenue falls into.
Ionis Pharmaceuticals's current Enterprise Value is $5,949.6 Mil.
Ionis Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $717.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals's share price for today is $42.77.
Ionis Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.71.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ionis Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IONS has been successfully added to your 